Rohit Bhattacharjee, Amity University, Kolkata
CK2 is a constitutively active Ser/Thr protein kinase, which phosphorylates many substrates, controls signaling pathways, implicates plenty of human sicknesses. Its best-recorded job is in cancer, where it manages every single hallmark of malignancy. Other notable functions of CK2 are in human diseases; specifically, viruses in viral infections misuse host cell CK2 for their life cycle. CK2 is likewise viewed as an emerging objective for neurological sicknesses, irritation and autoimmune problems, different ophthalmic pathologies, diabetes, and obesity. Furthermore, CK2 activity has been related to cardiovascular disorders, as heart ischemia-reperfusion injury, atherosclerosis, and cardiovascular hypertrophy. The theory of considering CK2 inhibition for cystic fibrosis treatments has been likewise engaged for a long time. Besides, mental disorders and conditions because of CK2 changes have been as of late recognized. On these bases, CK2 is arising as an undeniably alluring target in different fields of human medication, with the benefit that several quite certain and effective inhibitors are now accessible. As of late, additionally, SARS-CoV-2, the virus causing the COVID-19 pandemic, has been found to improve CK2 activity and initiate the phosphorylation of other CK2 substrates.
CK2 (formerly called casein kinase 2 or CK-II) is one of the first recognized protein kinases. It phosphorylates many physiological substrates and is one of the significant contributors in the age of the human phospho-proteome. Mammalian CK2 is a tetrameric protein, made out of two catalytic and two regulatory subunits. The catalytic ones may be addressed either by α or α′, basically the same however encoded by two unique genes, CSNK2A1 and CSNK2A2, separately, while only one human CK2 regulatory subunit exists, β, encoded by the CSNK2B gene. The regulatory roles of β are restricted to safeguarding the enzyme steadiness and driving the determination of substrates. Long story short, CK2 is constitutively dynamic and chemically competent in its monomeric structure.
Given its activity in a few dysregulated pathways in human pathologies, CK2 is viewed as a medication target. A benefit is addressed by the wide range of inhibitors effectively accessible and possibly in the possession of clinicians. The particularity is additionally expanded on account of the alleged bi-substrate inhibitors. Additional information on CK2 capacities in human disorders is central either to design its focusing as conceivable therapy or, regardless, to all the more likely comprehend the atomic components underlying the pathogenic cycles and to design the right intercessions for better-customized treatment. For certain disorders, Protein Kinase CK2 can be unquestionably perceived as a drug target.
Specifically, promising anticancer impacts have been gotten with Protein Kinase CK2 inhibitors in countless studies, in cell and animal models, and clinical trials are continuous with the CK2 inhibitors. Be that as it may, little is known on the bioavailability and pharmacokinetics of CK2 inhibitors; just preliminary studies are published. For different pathologies, like cardiovascular disorders, the real attainability of treatments dependent on CK2 focusing is less obvious, frequently because of dubious reports. A few reports recommend a valuable impact of CK2 inhibition, however conclusions are ambiguous, yet, and proof of CK2 physiological and fundamental activities ought to be additionally thought of. In the eye, CK2 inhibition forestalls obsessive retina angiogenesis, yet, on the opposite side, a few CK2-dependant phosphorylations are vital for the appropriate eye improvement. Thus, it must be resolved whether CK2 hindrance is fitting to forestall the high multiplying rate needed for abnormal angiogenesis, without harming typical retinal functions. In a few mental problems, the ramifications of Protein Kinase CK2 is undoubted, be that as it may, its movement may be either instrumental to the pathology (concerning depression), or rather fundamental for permitting the right physiological functions and forestalling the sickness (autism, ADHD, and schizophrenia) and ought to be protected or even elevate to forestall the psychological disorder. Future investigations will unveil whether various methodologies for CK2 focusing will be conceivable, including genetic engineering.
Also read: Hif1a gene in Microglia: A hope for Alzheimer’s patients
Source:- Borgo, C., D’Amore, C., Sarno, S. et al. Protein kinase CK2: a potential therapeutic target for diverse human diseases. Sig Transduct Target Ther 6, 183 (2021). https://doi.org/10.1038/s41392-021-00567-https://www.nature.com/articles/s41392-021-00567-7
One thought on “Protein Kinase CK2 : The drug target for diverse human disorders”